Here are five companies in which GV has chosen to invest, according to Becker’s coverage since Aug. 23:
- GV joined in with Pittsburgh-based UPMC Enterprises to participate in a $51 million series B financing round for drug discovery company Cerevance.
- The venture capital arm invested $28.1 million in mental health startup Firsthand.
- GV joined with Boston-based Mass General Brigham to participate in the $32 million seed funding round for Rippl, a digital mental health company focusing on older adults.
- GV took part in a $72.5 million series A financing round for Pretzel Therapeutics, a company that uses mitochondrial biology to treat disease.
- GV participated in a $65 million series A financing round for precision medicine startup Vicinitas Therapeutics.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.